-
1 week ago | 
941theduke.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 week ago | 
wimz.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 week ago | 
947thebeast.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 week ago | 
krro.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 week ago | 
hot96.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 week ago | 
wtbx.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 week ago | 
wxerfm.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 week ago | 
939thegame.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 week ago | 
radiousa.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 week ago | 
wifc.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
